Definium Therapeutics (DFTX) Other financing activities (2021 - 2026)

Definium Therapeutics (DFTX) has reported Other financing activities for 6 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other financing activities rose 404.64% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $259.8 million (up 4.54% YoY), while the FY2025 annual figure was $258.9 million, up 3.54% from the prior year.
• Other financing activities eased to $1.2 million in Q1 2026 per DFTX's latest filing, from $257.9 million in the prior quarter.
• Across five years, Other financing activities topped out at $257.9 million in Q4 2025 and bottomed at -$688000.0 in Q4 2023.
• Historically, Other financing activities has averaged $43.9 million across 5 years, with a median of $1.0 million in 2025.
• Annual changes were most pronounced in 2023 — Other financing activities tumbled 104.04% — and 2024, when it surged 35793.02%.
• Definium Therapeutics' Other financing activities stood at $17.0 million in 2022, then sank by 104.04% to -$688000.0 in 2023, then soared by 35793.02% to $245.6 million in 2024, then advanced by 5.0% to $257.9 million in 2025, then sank by 99.54% to $1.2 million in 2026.
• Business Quant data shows DFTX's Other financing activities at $1.2 million in Q1 2026, $257.9 million in Q4 2025, and $818000.0 in Q3 2025.